세계의 당뇨병성 케톤산증(DKA) 시장 보고서(2025년)

Diabetic Ketoacidosis (DKA) Global Market Report 2025

US $ 4,490 ￦ 6,319,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,134,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,949,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

당뇨병성 케톤산증(DKA) 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 연평균 성장률(CAGR) 8.5%로 성장할 전망이며, 43억 7,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 인슐린 전달체계 진보, 지속적 포도당 모니터링 채용 확대, 당뇨병 관련 합병증에 대한 의식 고조, 당뇨병 관리를 위한 원격 의료 확대, 헬스케어 지출 증가가 견인할 것으로 예상됩니다. 이 기간 주요 동향으로는 당뇨병 치료에서 인공지능의 통합, 클로즈드 루프 인슐린 전달 시스템 개발, 개별화 의료, 최첨단 기술, 혁신적 치료 등이 있습니다.

비만 유병률 증가는 당뇨병성 케톤산증(DKA) 시장의 확대에 기여하고 있습니다. 비만은 체지방의 과도한 축적을 특징으로 하는 병세이며, 건강에 악영향을 미쳐 다양한 질환의 위험을 높일 수 있습니다. 비만율 증가는 가공식품, 설탕, 지방이 많은 건강하지 못한 식사, 신체 활동이 제한된 앉기 쉬운 라이프 스타일, 장시간 스크린 이용, 저렴한 건강식품 및 헬스케어에 대한 접근 제한과 같은 사회경제적 과제 등 몇 가지 요인에 의해 초래되고 있습니다. 비만은 인슐린 저항성을 촉진해 제2형 당뇨병 개발로 이어짐으로써 당뇨병성 케톤산증(DKA)의 위험을 높입니다. 예를 들어 2024년 3월 스위스에 본부를 둔 정부 간 기관인 세계보건기구(WHO)는 전 세계 약 8명 중 1명이 비만의 영향을 받고 있다고 보고했습니다. 이 중에는 25억 명의 성인(18세 이상)이 포함되어 있고, 8억 9,000만 명이 비만으로 분류되어 있습니다. 성인 중 43%가 과체중이었고 16%가 비만이었습니다. 게다가 5세 미만의 과체중 어린이는 3,700만 명에 달했습니다. 그 결과 비만의 만연이 당뇨병성 케톤산증 시장의 확대를 견인하고 있습니다.

당뇨병성 케톤산증 시장의 주요 기업은 조기 발견을 강화하고, 혈당와 케톤체 수준의 관리를 개선하며, 결국 당뇨병 환자의 DKA 에피소드의 빈도와 중증도를 저감하기 위해서 지속 글루코스 모니터링 툴 등의 첨단 기술의 개발을 우선하고 있습니다. 지속 포도당 모니터링(CGM) 도구는 포도당 수준을 실시간으로 추적하도록 설계된 장치로 당뇨병 환자가 혈당을 효과적으로 모니터링하고 조정할 수 있도록 합니다. 예를 들어 2022년 6월 미국 의료기기 회사인 애벗 래버러토리스는 포도당과 케톤체 수준을 모두 실시간으로 추적할 수 있는 혁신적이고 지속적인 포도당 케톤 감시 시스템을 발표했습니다. 이 시스템은 포도당과 케톤체 모니터링을 통합해 환자의 대사 상태를 포괄적으로 파악할 수 있습니다. 두 지표를 동시에 측정하면 당뇨병성 케톤산증(DKA)와 같은 잠재적인 당뇨병 합병증이 심각해지기 전에 조기 발견이 쉬워집니다. 지속적인 모니터링을 위해 설계된 이 시스템은 수동 검사가 필요 없이 잦은 데이터 업데이트를 제공하여 사용자의 편의성을 높이고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

• 세계의 당뇨병성 케톤산증(DKA) PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 당뇨병성 케톤산증(DKA) 시장 : 성장률 분석
• 세계의 당뇨병성 케톤산증(DKA) 시장 실적 : 규모 및 성장(2019-2024년)
• 세계의 당뇨병성 케톤산증(DKA) 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
• 세계의 당뇨병성 케톤산증(DKA) 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 당뇨병성 케톤산증(DKA) 시장 : 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 소아 당뇨병성 케톤산증
• 성인 당뇨병성 케톤산증
• 세계의 당뇨병성 케톤산증(DKA) 시장 : 치료 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 체액 보충
• 전해질 보급
• 인슐린 요법
• 중간형 인슐린
• 장시간 작용형 인슐린
• 세계의 당뇨병성 케톤산증(DKA) 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 오랄
• 비경구
• 기타 투여 경로
• 세계의 당뇨병성 케톤산증(DKA) 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 온라인 채널
• 오프라인 채널
• 세계의 당뇨병성 케톤산증(DKA) 시장 : 최종 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 외래 진료 센터
• 전문 클리닉
• 세계의 당뇨병성 케톤산증(DKA) 시장 : 소아 당뇨병성 케톤산증 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 경도 소아 DKA
• 중등도 소아 DKA
• 중증 소아 DKA
• 세계의 당뇨병성 케톤산증(DKA) 시장 : 성인 당뇨병성 케톤산증 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 경도 성인 DKA
• 중등도 성인 DKA
• 중증 성인 DKA

제7장 지역별 및 국가별 분석

• 세계의 당뇨병성 케톤산증(DKA) 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 당뇨병성 케톤산증(DKA) 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

• 당뇨병성 케톤산증(DKA) 시장 : 경쟁 구도
• 당뇨병성 케톤산증(DKA) 시장 : 기업 프로파일
  • Merck And Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석
  • Bristol Myers Squibb 개요, 제품 및 서비스, 전략 및 재무 분석
  • Novartis AG 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Roche Holding AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• B. Braun Medical Inc.
• Fresenius Kabi
• Merit Pharmaceutical
• Oramed Pharmaceuticals Inc.
• ICU Medical Inc.
• Tonghua Dongbao Pharmaceutical Co. Ltd.
• Wockhardt Ltd.
• Biocon Limited

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

• 당뇨병성 케톤산증(DKA) 시장(2029년) : 새로운 기회를 제공하는 국가
• 당뇨병성 케톤산증(DKA) 시장(2029년) : 새로운 기회를 제공하는 부문
• 당뇨병성 케톤산증(DKA) 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

AJY

영문 목차

영문목차

Diabetic ketoacidosis (DKA) is a serious complication of diabetes in which the body produces excessive blood acids known as ketones due to inadequate insulin levels. This condition can lead to dehydration, electrolyte imbalances, and potentially life-threatening complications. It is essential for diagnosing and managing severe metabolic imbalances in diabetic patients to prevent risks such as dehydration, organ failure, and coma.

The primary types of diabetic ketoacidosis (DKA) include pediatric diabetic ketoacidosis and adult diabetic ketoacidosis. Pediatric DKA occurs in children and adolescents with diabetes and is often triggered by insulin deficiency, infections, or other stress factors. Treatment options involve fluid replacement, electrolyte replenishment, and insulin therapy, including intermediate-acting and long-acting insulin. The available administration routes include oral, parenteral, and other methods. These treatments are distributed through various channels, both online and offline, and are utilized by multiple end users, such as hospitals, ambulatory care centers, and specialty clinics.

The diabetic ketoacidosis (DKA) market research report is one of a series of new reports from The Business Research Company that provides diabetic ketoacidosis (DKA) market statistics, including diabetic ketoacidosis (DKA) industry global market size, regional shares, competitors with diabetic ketoacidosis (DKA) market share, detailed diabetic ketoacidosis (DKA) market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic ketoacidosis (DKA) industry. This diabetic ketoacidosis (DKA) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetic ketoacidosis (DKA) market size has grown strongly in recent years. It will grow from $2.90 billion in 2024 to $3.16 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period can be attributed to the rising prevalence of diabetes, delayed diagnosis of type 1 diabetes, poor adherence to insulin therapy, increasing obesity rates, and the lack of diabetes education programs.

The diabetic ketoacidosis (DKA) market size is expected to see strong growth in the next few years. It will grow to $4.37 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period is expected to be driven by advancements in insulin delivery systems, the increasing adoption of continuous glucose monitoring, greater awareness of diabetes-related complications, the expansion of telemedicine for diabetes management, and rising healthcare expenditures. Key trends during this period include the integration of artificial intelligence in diabetes care, the development of closed-loop insulin delivery systems, personalized medicine, cutting-edge technologies, and innovative therapies.

The rising prevalence of obesity is contributing to the expansion of the diabetic ketoacidosis (DKA) market. Obesity is a medical condition characterized by excessive accumulation of body fat, which can have adverse health effects and increase the risk of various diseases. The increase in obesity rates is driven by several factors, including unhealthy diets rich in processed foods, sugars, and fats, sedentary lifestyles with limited physical activity, prolonged screen time, and socioeconomic challenges such as limited access to affordable healthy food and healthcare. Obesity heightens the risk of diabetic ketoacidosis (DKA) by promoting insulin resistance and leading to the development of type 2 diabetes, which can result in poor blood sugar control and subsequent DKA episodes. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people worldwide were affected by obesity. This included 2.5 billion adults (aged 18 and older) who were overweight, with 890 million classified as obese. Among adults, 43% were overweight, and 16% were obese. Additionally, the number of overweight children under the age of five reached 37 million. Consequently, the growing prevalence of obesity is driving the expansion of the diabetic ketoacidosis market.

Leading companies in the diabetic ketoacidosis market are prioritizing the development of advanced technologies, such as continuous glucose monitoring tools, to enhance early detection, improve blood glucose and ketone level management, and ultimately reduce the frequency and severity of DKA episodes in individuals with diabetes. Continuous glucose monitoring (CGM) tools are devices designed to track glucose levels in real time, allowing individuals with diabetes to monitor and regulate their blood sugar levels effectively. For instance, in June 2022, Abbott Laboratories, a US-based medical device company, introduced an innovative continuous glucose-ketone monitoring system that enables real-time tracking of both glucose and ketone levels. This system integrates glucose and ketone monitoring, offering a comprehensive view of a patient's metabolic state. By measuring both metrics simultaneously, it facilitates the early detection of potential diabetic complications, such as diabetic ketoacidosis (DKA), before they become critical. Designed for continuous monitoring, the system provides frequent data updates without requiring manual testing, ensuring greater convenience for users.

In September 2023, Abbott Laboratories, a US-based medical device company, acquired Bigfoot Biomedical for an undisclosed amount. This acquisition strengthens Abbott's diabetic care portfolio, which already features the globally recognized FreeStyle Libre continuous glucose monitoring technology. Bigfoot Biomedical Inc. is a US-based company specializing in medical technology for diabetic care.

Major players in the diabetic ketoacidosis (DKA) market are Merck And Co. Inc., Pfizer Inc., Sanofi S.A., Bristol Myers Squibb, Novartis AG, Roche Holding AG, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., B. Braun Medical Inc., Fresenius Kabi, Merit Pharmaceutical, Oramed Pharmaceuticals Inc., ICU Medical Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., Wockhardt Ltd., Biocon Limited.

North America was the largest region in the diabetic ketoacidosis (DKA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diabetic ketoacidosis (DKA) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the diabetic ketoacidosis (DKA) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetic ketoacidosis (DKA) market includes revenues earned by entities by providing services such as blood glucose monitoring, ketone testing, and arterial blood gas analysis and related products such as blood glucose monitors, continuous glucose monitoring (CGM) devices, syringes, insulin pens, and insulin pumps. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetic Ketoacidosis (DKA) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic ketoacidosis (dka) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetic ketoacidosis (dka) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The diabetic ketoacidosis (dka) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Pediatric Diabetic Ketoacidosis, Adult Diabetic Ketoacidosis
• 2) By Treatment Type: Fluid Replacement, Electrolyte Replacement, Insulin Therapy, Intermediate-Acting Insulin, Long-Acting Insulin
• 3) By Route of Administration: Oral, Parenteral, Other
• 4) By Distribution Channel: Online Channel, Offline Channel
• 5) By End Use: Hospitals, Ambulatory Care Center, Specialty Clinics
• Subsegments:
• 1) By Pediatric Diabetic Ketoacidosis: Mild Pediatric DKA; Moderate Pediatric DKA; Severe Pediatric DKA
• 2) By Adult Diabetic Ketoacidosis: Mild Adult DKA; Moderate Adult DKA; Severe Adult DKA
• Companies Mentioned: Merck And Co. Inc.; Pfizer Inc.; Sanofi S.A.; Bristol Myers Squibb; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Diabetic Ketoacidosis (DKA) Market Characteristics

3. Diabetic Ketoacidosis (DKA) Market Trends And Strategies

4. Diabetic Ketoacidosis (DKA) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Diabetic Ketoacidosis (DKA) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Diabetic Ketoacidosis (DKA) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Diabetic Ketoacidosis (DKA) Market Growth Rate Analysis
• 5.4. Global Diabetic Ketoacidosis (DKA) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Diabetic Ketoacidosis (DKA) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Diabetic Ketoacidosis (DKA) Total Addressable Market (TAM)

6. Diabetic Ketoacidosis (DKA) Market Segmentation

• 6.1. Global Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Diabetic Ketoacidosis
• Adult Diabetic Ketoacidosis
• 6.2. Global Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluid Replacement
• Electrolyte Replacement
• Insulin Therapy
• Intermediate-Acting Insulin
• Long-Acting Insulin
• 6.3. Global Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes of Administration
• 6.4. Global Diabetic Ketoacidosis (DKA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Channel
• Offline Channel
• 6.5. Global Diabetic Ketoacidosis (DKA) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Care Center
• Specialty Clinics
• 6.6. Global Diabetic Ketoacidosis (DKA) Market, Sub-Segmentation Of Pediatric Diabetic Ketoacidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Pediatric DKA
• Moderate Pediatric DKA
• Severe Pediatric DKA
• 6.7. Global Diabetic Ketoacidosis (DKA) Market, Sub-Segmentation Of Adult Diabetic Ketoacidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Adult DKA
• Moderate Adult DKA
• Severe Adult DKA

7. Diabetic Ketoacidosis (DKA) Market Regional And Country Analysis

• 7.1. Global Diabetic Ketoacidosis (DKA) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Diabetic Ketoacidosis (DKA) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Diabetic Ketoacidosis (DKA) Market

• 8.1. Asia-Pacific Diabetic Ketoacidosis (DKA) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Diabetic Ketoacidosis (DKA) Market

• 9.1. China Diabetic Ketoacidosis (DKA) Market Overview
• 9.2. China Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Diabetic Ketoacidosis (DKA) Market

• 10.1. India Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Diabetic Ketoacidosis (DKA) Market

• 11.1. Japan Diabetic Ketoacidosis (DKA) Market Overview
• 11.2. Japan Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Diabetic Ketoacidosis (DKA) Market

• 12.1. Australia Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Diabetic Ketoacidosis (DKA) Market

• 13.1. Indonesia Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Diabetic Ketoacidosis (DKA) Market

• 14.1. South Korea Diabetic Ketoacidosis (DKA) Market Overview
• 14.2. South Korea Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Diabetic Ketoacidosis (DKA) Market

• 15.1. Western Europe Diabetic Ketoacidosis (DKA) Market Overview
• 15.2. Western Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Diabetic Ketoacidosis (DKA) Market

• 16.1. UK Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Diabetic Ketoacidosis (DKA) Market

• 17.1. Germany Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Diabetic Ketoacidosis (DKA) Market

• 18.1. France Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Diabetic Ketoacidosis (DKA) Market

• 19.1. Italy Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Diabetic Ketoacidosis (DKA) Market

• 20.1. Spain Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Diabetic Ketoacidosis (DKA) Market

• 21.1. Eastern Europe Diabetic Ketoacidosis (DKA) Market Overview
• 21.2. Eastern Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Diabetic Ketoacidosis (DKA) Market

• 22.1. Russia Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Diabetic Ketoacidosis (DKA) Market

• 23.1. North America Diabetic Ketoacidosis (DKA) Market Overview
• 23.2. North America Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Diabetic Ketoacidosis (DKA) Market

• 24.1. USA Diabetic Ketoacidosis (DKA) Market Overview
• 24.2. USA Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Diabetic Ketoacidosis (DKA) Market

• 25.1. Canada Diabetic Ketoacidosis (DKA) Market Overview
• 25.2. Canada Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Diabetic Ketoacidosis (DKA) Market

• 26.1. South America Diabetic Ketoacidosis (DKA) Market Overview
• 26.2. South America Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Diabetic Ketoacidosis (DKA) Market

• 27.1. Brazil Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Diabetic Ketoacidosis (DKA) Market

• 28.1. Middle East Diabetic Ketoacidosis (DKA) Market Overview
• 28.2. Middle East Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Diabetic Ketoacidosis (DKA) Market

• 29.1. Africa Diabetic Ketoacidosis (DKA) Market Overview
• 29.2. Africa Diabetic Ketoacidosis (DKA) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Diabetic Ketoacidosis (DKA) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Diabetic Ketoacidosis (DKA) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Diabetic Ketoacidosis (DKA) Market Competitive Landscape And Company Profiles

• 30.1. Diabetic Ketoacidosis (DKA) Market Competitive Landscape
• 30.2. Diabetic Ketoacidosis (DKA) Market Company Profiles
  • 30.2.1. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Diabetic Ketoacidosis (DKA) Market Other Major And Innovative Companies

• 31.1. Roche Holding AG
• 31.2. GlaxoSmithKline plc
• 31.3. Eli Lilly and Company
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Novo Nordisk A/S
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. B. Braun Medical Inc.
• 31.9. Fresenius Kabi
• 31.10. Merit Pharmaceutical
• 31.11. Oramed Pharmaceuticals Inc.
• 31.12. ICU Medical Inc.
• 31.13. Tonghua Dongbao Pharmaceutical Co. Ltd.
• 31.14. Wockhardt Ltd.
• 31.15. Biocon Limited

32. Global Diabetic Ketoacidosis (DKA) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diabetic Ketoacidosis (DKA) Market

34. Recent Developments In The Diabetic Ketoacidosis (DKA) Market

35. Diabetic Ketoacidosis (DKA) Market High Potential Countries, Segments and Strategies

• 35.1 Diabetic Ketoacidosis (DKA) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Diabetic Ketoacidosis (DKA) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Diabetic Ketoacidosis (DKA) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료